Gilead Terminates Phase III Clinical Trial of Ambrisentan in Patients with Idiopathic Pulmonary Fibrosis
December 22 2010 - 5:00PM
Business Wire
Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is
stopping ARTEMIS-IPF, the company’s ongoing Phase III clinical
trial of ambrisentan in patients with idiopathic pulmonary fibrosis
(IPF), due to lack of efficacy. This decision follows an interim
analysis of unblinded efficacy and safety data by the study’s Data
Monitoring Committee (DMC) and review of those data by Gilead,
which did not show evidence of a treatment benefit in the group of
patients randomized to receive ambrisentan. Gilead is conducting a
thorough review of the data and will communicate the full results
of this analysis to the medical community when they are
available.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company’s mission is to advance the care of
patients suffering from life-threatening diseases worldwide.
Headquartered in Foster City, California, Gilead has operations in
North America, Europe and Australia.
Forward-Looking
Statement
This press release includes forward-looking statements, within
the meaning of the Private Securities Litigation Reform Act of
1995, that are subject to risks, uncertainties and other factors
that could cause actual results to differ materially from those
referred to in the forward-looking statements, including
risks that development stage compounds may fail during
clinical testing. The reader is cautioned not to rely on these
forward-looking statements. These and other risks are described in
detail in Gilead’s Quarterly Report on Form 10-Q for the quarter
ended September 30, 2010, as filed with the U.S. Securities and
Exchange Commission. All forward-looking statements are based on
information currently available to Gilead, and Gilead assumes no
obligation to update any such forward-looking statements.
For more information on Gilead Sciences, please
visit the company's website at www.gilead.com or call Gilead Public
Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2024 to Jun 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2023 to Jun 2024